1.T-cell non-Hodgkin's lymphoma originating in the wall of chronic tuberculous empyema: one case report.
Woo Chul SONG ; Jin Ho CHOI ; Chang Yul MYEONG ; Ho Seung SHIN ; Byeong Joo KIM ; Hee Chul PARK ; Ki Woo HONG ; Hea Kyeong AHN
The Korean Journal of Thoracic and Cardiovascular Surgery 1992;25(10):1102-1106
No abstract available.
Empyema, Tuberculous*
;
Lymphoma, Non-Hodgkin*
;
T-Lymphocytes*
2.A Case of Paraplegia Following Endovascular Stent Repair of Descending Thoracic Aortic Aneurysm.
Min Young LEE ; Myung Goo LEE ; Kyung Soon HONG ; Chang Yul LEE ; Kyu Tae PARK ; Chan Woo LEE ; Myeong Shin RYU ; Young Muk KIM ; Dae Hyun HWANG
Korean Circulation Journal 2011;41(3):160-163
Paraplegia secondary to spinal cord infarction is a recognized complication of open thoracic and thoracoabdominal aortic aneurysm (TAA) repair. TAA is serious and unpredictable condition. Therefore, aortic repair requires thorough information on managing the potential complications will facilitate improve control the problem. We report the symptoms and management of paraplegia in a patient who underwent stent insertion as TAA.
Aortic Aneurysm, Abdominal
;
Aortic Aneurysm, Thoracic
;
Humans
;
Infarction
;
Paraplegia
;
Spinal Cord
;
Spinal Cord Ischemia
;
Stents
3.Bioresorbable Vascular Scaffold Korean Expert Panel Report.
Jung Min AHN ; Duk Woo PARK ; Sung Jin HONG ; Young Keun AHN ; Joo Yong HAHN ; Won Jang KIM ; Soon Jun HONG ; Chang Wook NAM ; Do Yoon KANG ; Seung Yul LEE ; Woo Jung CHUN ; Jung Ho HEO ; Deok Kyu CHO ; Jin Won KIM ; Sung Ho HER ; Sang Wook KIM ; Sang Yong YOO ; Myeong Ki HONG ; Seung Jea TAHK ; Kee Sik KIM ; Moo Hyun KIM ; Yangsoo JANG ; Seung Jung PARK
Korean Circulation Journal 2017;47(6):795-810
Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
Coronary Disease
;
Drug Liberation
;
Drug-Eluting Stents
;
Humans
;
Korea
;
Stents
;
Thrombosis